nach oben

Erschienen in:

01.03.2018 | Letter to the Editor

Authors’ Reply to Mona Kargar and Colleagues’ Comment on “Adverse Drug Reaction-Related Hospitalizations in Elderly Australians: A Prospective Cross-Sectional Study in Two Tasmanian Hospitals”

verfasst von: Nibu Parameswaran Nair, Leanne Chalmers, Bonnie J. Bereznicki, Colin Curtain, Gregory M. Peterson, Michael Connolly, Luke R. Bereznicki

Erschienen in: Drug Safety | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …

Kargar M, Ahmadvand A, Gholami K. Comment on: “Adverse drug reaction-related hospitalizations in elderly Australians: a prospective cross-sectional study in two Tasmanian hospitals”. Drug Saf. 2017. https://doi.org/10.1007/s40264-017-0612-4.PubMed

Parameswaran Nair N, Chalmers L, Bereznicki BJ, Curtain C, Peterson GM, Connolly M, et al. Adverse drug reaction-related hospitalizations in elderly Australians: a prospective cross-sectional study in two Tasmanian Hospitals. Drug Saf. 2017;40(7):597–606.CrossRefPubMed

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.CrossRefPubMed

Seger D, Barker K, McNaughton C. Misuse of the Naranjo adverse drug reaction probability scale in toxicology. Clin Toxicol (Phila). 2013 Jul;51(6):461–6.CrossRef

Parameswaran Nair N, Chalmers L, Connolly M, Bereznicki BJ, Peterson GM, Curtain C, et al. Prediction of hospitalization due to adverse drug reactions in elderly community-dwelling patients (The PADR-EC Score). PLoS One. 2016;11(10):e0165757.CrossRefPubMedPubMedCentral

Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. Oxford: Oxford University Press; 1991. p. 18–45.

Titel: Authors’ Reply to Mona Kargar and Colleagues’ Comment on “Adverse Drug Reaction-Related Hospitalizations in Elderly Australians: A Prospective Cross-Sectional Study in Two Tasmanian Hospitals”
verfasst von: Nibu Parameswaran Nair
Leanne Chalmers
Bonnie J. Bereznicki
Colin Curtain
Gregory M. Peterson
Michael Connolly
Luke R. Bereznicki
Publikationsdatum: 01.03.2018
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 3/2018
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.1007/s40264-017-0613-3

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Using Human ‘Experiments of Nature’ to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors

Evaluation of ‘Definite’ Anaphylaxis Drug Allergy Alert Overrides in Inpatient and Outpatient Settings

Severe Physical Complications among Survivors of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis

Comment on: “Adverse Drug Reaction-Related Hospitalizations in Elderly Australians: A Prospective Cross-Sectional Study in Two Tasmanian Hospitals”

Utilisation and Safety of Deferasirox: Results from an Observational Cohort Study in England

Can SGLT2 Inhibitors Cause Acute Renal Failure? Plausible Role for Altered Glomerular Hemodynamics and Medullary Hypoxia